{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:28:50Z","timestamp":1793964530232,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":222,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinsp.2026.101093","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:46:04Z","timestamp":1788849964000},"page":"101093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cumulative thalidomide exposure, peripheral neuropathy, and clinical outcomes in pediatric and very early-onset inflammatory bowel disease: a retrospective cohort study"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8412-033X","authenticated-orcid":false,"given":"Jing","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2819-4439","authenticated-orcid":false,"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5574-623X","authenticated-orcid":false,"given":"Zebin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1703-5161","authenticated-orcid":false,"given":"Zhongqiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2709-6838","authenticated-orcid":false,"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9199-2380","authenticated-orcid":false,"given":"Zhuyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-2631","authenticated-orcid":false,"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9477-9621","authenticated-orcid":false,"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinsp.2026.101093_bib0001","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinsp.2026.101093_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105120","article-title":"Biological therapy in pediatric age","volume":"161","author":"Penagini","year":"2020","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.clinsp.2026.101093_bib0003","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ibd\/izaa054","article-title":"Distribution and cytokine profile of peripheral B cell subsets is perturbed in pediatric IBD and partially restored during a successful IFX therapy","volume":"27","author":"Schnell","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.clinsp.2026.101093_bib0004","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinsp.2026.101093_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaf031","article-title":"Higher-dose infliximab induction achieves better maintenance trough levels in a national pediatric IBD cohort: a retrospective study","author":"Stenke","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101093_bib0006","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MPG.0000000000003551","article-title":"Progression to anti-TNF treatment in very early onset inflammatory bowel disease patients","volume":"75","author":"Eindor-Abarbanel","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101093_bib0007","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/MPG.0000000000001742","article-title":"Secondary loss of response to infliximab in pediatric Crohn disease: does it matter how and when we start?","volume":"66","author":"Bolia","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101093_bib0008","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MIB.0000000000001051","article-title":"Multicentric case-control study on azathioprine dose and pharmacokinetics in early-onset pediatric inflammatory bowel disease","volume":"23","author":"Stocco","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101093_bib0009","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","article-title":"Infliximab in young paediatric IBD patients: it is all about the dosing","volume":"179","author":"Jongsma","year":"2020","journal-title":"Eur J Pediatr"},{"issue":"9423","key":"10.1016\/j.clinsp.2026.101093_bib0010","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clinsp.2026.101093_bib0011","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101093_bib0012","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ibd\/izad018","article-title":"Efficacy and tolerance of thalidomide in patients with very early onset inflammatory bowel disease","volume":"30","author":"Bramuzzo","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.clinsp.2026.101093_bib0013","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1097\/MIB.0000000000001195","article-title":"Risk factors and outcomes of thalidomide-induced peripheral neuropathy in a pediatric inflammatory bowel disease cohort","volume":"23","author":"Bramuzzo","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101093_bib0014","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jcpt.13196","article-title":"Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: a systematic review","volume":"45","author":"Qiu","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101093_bib0015","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.cgh.2017.02.029","article-title":"Endoscopic and histologic healing in children with inflammatory bowel diseases treated with thalidomide","volume":"15","author":"Lazzerini","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101093_bib0016","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101093_bib0017","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jgh.14939","article-title":"Long-term outcomes of thalidomide in pediatric Crohn's disease","volume":"35","author":"Wang","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101093_bib0018","first-page":"1078","article-title":"Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the Pediatric IBD Porto Group of ESPGHAN","volume":"11","author":"Birimberg-Schwartz","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinsp.2026.101093_bib0019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jpeds.2016.07.040","article-title":"Longitudinal patterns of thalidomide neuropathy in children and adolescents","volume":"178","author":"Liew","year":"2016","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101093_bib0020","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: a comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101093_bib0021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2036.2006.03211.x","article-title":"Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.clinsp.2026.101093_bib0022","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","article-title":"Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study","volume":"62","author":"Cavaletti","year":"2004","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.clinsp.2026.101093_bib0023","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.3748\/wjg.v29.i24.3855","article-title":"Comparison and development of machine learning for thalidomide-induced peripheral neuropathy prediction of refractory Crohn's disease in Chinese population","volume":"29","author":"Mao","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101093_bib0024","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clinsp.2026.101093_bib0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp.2008.147892","article-title":"Thalidomide and sensory neurotoxicity: a neurophysiological study","volume":"79","author":"Zara","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101093_bib0026","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-0039-1694747","article-title":"A clinician's approach to peripheral neuropathy","volume":"39","author":"Siao","year":"2019","journal-title":"Semin Neurol"},{"issue":"3","key":"10.1016\/j.clinsp.2026.101093_bib0027","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pediatrneurol.2007.11.004","article-title":"Childhood thalidomide neuropathy: a clinical and neurophysiologic study","volume":"38","author":"Priolo","year":"2008","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101093_bib0028","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/MPG.0000000000000533","article-title":"Infliximab therapy in pediatric patients 7 years of age and younger","volume":"59","author":"Kelsen","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101093_bib0029","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/2050640619847592","article-title":"Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study","volume":"7","author":"Bramuzzo","year":"2019","journal-title":"United European Gastroenterol J"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:14:37Z","timestamp":1793963677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593226002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["S1807593226002206"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101093","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cumulative thalidomide exposure, peripheral neuropathy, and clinical outcomes in pediatric and very early-onset inflammatory bowel disease: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101093"}}